HK1064668A1 - Polycyclic guanine phosphodiesterase v inhibitors - Google Patents

Polycyclic guanine phosphodiesterase v inhibitors

Info

Publication number
HK1064668A1
HK1064668A1 HK04107396A HK04107396A HK1064668A1 HK 1064668 A1 HK1064668 A1 HK 1064668A1 HK 04107396 A HK04107396 A HK 04107396A HK 04107396 A HK04107396 A HK 04107396A HK 1064668 A1 HK1064668 A1 HK 1064668A1
Authority
HK
Hong Kong
Prior art keywords
inhibitors
polycyclic guanine
phosphodiesterase
guanine phosphodiesterase
polycyclic
Prior art date
Application number
HK04107396A
Other languages
English (en)
Inventor
Asberom Theodros
Hu Yueqing
Dmitri A Pissarnitski
Xu Ruo
Wang Yuguang
Chackalamannil Samuel
John W Clader
Andrew W Stamford
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of HK1064668A1 publication Critical patent/HK1064668A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/04Drugs for disorders of the urinary system for urolithiasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK04107396A 2001-08-28 2004-09-24 Polycyclic guanine phosphodiesterase v inhibitors HK1064668A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31539501P 2001-08-28 2001-08-28
PCT/US2002/027181 WO2003020724A1 (en) 2001-08-28 2002-08-26 Polycyclic guanine phosphodiesterase v inhibitors

Publications (1)

Publication Number Publication Date
HK1064668A1 true HK1064668A1 (en) 2005-02-04

Family

ID=23224209

Family Applications (1)

Application Number Title Priority Date Filing Date
HK04107396A HK1064668A1 (en) 2001-08-28 2004-09-24 Polycyclic guanine phosphodiesterase v inhibitors

Country Status (13)

Country Link
US (1) US6969719B2 (de)
EP (1) EP1421084B1 (de)
JP (2) JP4450365B2 (de)
CN (2) CN1781920A (de)
AR (1) AR036674A1 (de)
AT (1) ATE395349T1 (de)
CA (1) CA2457944C (de)
DE (1) DE60226615D1 (de)
ES (1) ES2302835T3 (de)
HK (1) HK1064668A1 (de)
MX (1) MXPA04001891A (de)
PE (1) PE20030415A1 (de)
WO (1) WO2003020724A1 (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020091129A1 (en) * 2000-11-20 2002-07-11 Mitradev Boolell Treatment of premature ejaculation
JP3945985B2 (ja) * 2000-12-28 2007-07-18 株式会社リコー デジタルカメラ装置
AU2002331064B2 (en) 2001-08-10 2007-08-23 Palatin Technologies, Inc. Peptidomimetics of biologically active metallopeptides
ATE395349T1 (de) * 2001-08-28 2008-05-15 Schering Corp Polycyclische guanin phosphodiesterase inhibitoren
US20030211040A1 (en) 2001-08-31 2003-11-13 Paul Greengard Phosphodiesterase activity and regulation of phosphodiesterase 1B-mediated signaling in brain
US6943171B2 (en) * 2001-11-09 2005-09-13 Schering Corporation Polycyclic guanine derivative phosphodiesterase V inhibitors
SI1509525T1 (sl) * 2002-05-31 2006-12-31 Schering Corp Postopek priprave inhibitorjev ksantinske fosfodiesteraze V in njihovih prekurzorjev
AR040232A1 (es) 2002-05-31 2005-03-23 Schering Corp Proceso para preparar inhibidores de la xantina fosfodiesterasa v, y precursores de los mismos
DE10230311A1 (de) * 2002-07-05 2004-01-22 Degussa Ag Verfahren zur Katalysator-freien Herstellung von O-Alkyl-N-cyanformimidaten
CA2546248A1 (en) * 2003-11-21 2005-06-09 Schering Corporation Phosphodiesterase v inhibitor formulations
EP1750862B1 (de) 2004-06-04 2011-01-05 Teva Pharmaceutical Industries Ltd. Irbesartan enthaltende pharmazeutische zusammensetzung
JP2008534505A (ja) * 2005-03-25 2008-08-28 メルク エンド カムパニー インコーポレーテッド テストステロンサプリメントおよび5アルファ−レダクターゼインヒビターによる男性の治療方法
JP5084725B2 (ja) 2005-06-06 2012-11-28 武田薬品工業株式会社 有機化合物
US20090118211A1 (en) * 2005-06-27 2009-05-07 Daniel Drai Compositions and Methods for Enhancement of Sexual Function
US20070042957A1 (en) * 2005-08-19 2007-02-22 Mayo Foundation For Medical Education And Research Type v phosphodiesterase inhibitors and natriuretic polypeptides
EP1919287A4 (de) * 2005-08-23 2010-04-28 Intra Cellular Therapies Inc Organische verbindungen zur behandlung einer verringerten dopamin-rezeptorsignalisierungs-aktivität
WO2007070426A2 (en) * 2005-12-09 2007-06-21 Mayo Foundation For Medical Education And Research Sexual dysfunction
JP2007290996A (ja) * 2006-04-24 2007-11-08 Ube Ind Ltd 4−アミノテトラヒドロピランの製法
EP2081431B1 (de) 2006-11-13 2013-01-16 Intra-Cellular Therapies, Inc. Organische verbindungen
WO2008070095A1 (en) 2006-12-05 2008-06-12 Intra-Cellular Therapies, Inc. Novel uses
WO2009002423A2 (en) * 2007-06-21 2008-12-31 Schering Corporation Polycyclic guanine derivatives and use thereof
CN104370920A (zh) 2007-12-06 2015-02-25 武田药品工业株式会社 有机化合物
MX2010006208A (es) 2007-12-06 2010-12-21 Intra Cellular Therapies Inc Compuestos organicos.
EA201170772A1 (ru) 2008-12-06 2012-03-30 Интра-Селлулар Терапиз, Инк. Органические соединения
ES2580759T3 (es) 2008-12-06 2016-08-26 Intra-Cellular Therapies, Inc. Compuestos orgánicos
US8633180B2 (en) 2008-12-06 2014-01-21 Intra-Cellular Therapies, Inc. Organic compounds
US8664207B2 (en) * 2008-12-06 2014-03-04 Intra-Cellular Therapies, Inc. Organic compounds
GEP20146029B (en) 2008-12-06 2014-02-10 Intracellular Therapies Inc Organic compounds
KR20110095881A (ko) 2008-12-06 2011-08-25 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
CN101747282A (zh) 2008-12-10 2010-06-23 上海特化医药科技有限公司 一类含有嘧啶酮苯基的化合物、其药物组合物及其制备方法和用途
EP2400970A4 (de) * 2009-02-25 2012-07-18 Intra Cellular Therapies Inc Pde-1-hemmer für augenleiden
JP2012526810A (ja) 2009-05-13 2012-11-01 イントラ−セルラー・セラピーズ・インコーポレイテッド 有機化合物
SG10201507362TA (en) 2009-08-05 2015-10-29 Intra Cellular Therapies Inc Novel Regulatory Proteins And Inhibitors
EP2523561A4 (de) * 2009-12-22 2013-06-05 Merck Sharp & Dohme 7,8-dihydro-1h-imidazo[2,1-b]purin-4(5h)-on-derivate und verwendungsverfahren
WO2011153136A1 (en) 2010-05-31 2011-12-08 Intra-Cellular Therapies, Inc. Organic compounds
US9763948B2 (en) 2010-05-31 2017-09-19 Intra-Cellular Therapies, Inc. PDE1 inhibitory compounds and methods
TW201206937A (en) 2010-05-31 2012-02-16 Intra Cellular Therapies Inc Organic compounds
JP5894148B2 (ja) 2010-05-31 2016-03-23 イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. 有機化合物
US10561656B2 (en) 2011-06-10 2020-02-18 Intra-Cellular Therapies, Inc. Organic compounds
US9801882B2 (en) 2013-02-17 2017-10-31 Intra-Cellular Therapies, Inc. Phosphodiesterase-1 inhibitors and their use in treatment of cardiovascular diseases
WO2014145617A2 (en) 2013-03-15 2014-09-18 Intra-Cellular Therapies, Inc. Novel uses
RU2679142C2 (ru) 2013-03-15 2019-02-06 Интра-Селлулар Терапиз, Инк. Органические соединения
JP6696904B2 (ja) 2014-01-08 2020-05-20 イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. 製剤および医薬組成物
ES2732442T3 (es) 2014-06-20 2019-11-22 Intra Cellular Therapies Inc Compuestos orgánicos
US9546175B2 (en) 2014-08-07 2017-01-17 Intra-Cellular Therapies, Inc. Organic compounds
US10285992B2 (en) 2014-08-07 2019-05-14 Intra-Cellular Therapies, Inc. Combinations of PDE1 inhibitors and NEP inhibitors and associated methods
TWI686394B (zh) 2014-08-07 2020-03-01 美商內胞醫療公司 有機化合物
CA2961212C (en) 2014-09-17 2024-02-06 Intra-Cellular Therapies, Inc. Compounds and methods
AU2015357498B2 (en) 2014-12-06 2019-09-12 Intra-Cellular Therapies, Inc. Organic compounds
RU2709786C2 (ru) 2014-12-06 2019-12-20 Интра-Селлулар Терапиз, Инк. Органические соединения
WO2017172795A1 (en) 2016-03-28 2017-10-05 Intra-Cellular Therapies, Inc. Novel compositions and methods
ES2906107T3 (es) 2016-09-12 2022-04-13 Intra Cellular Therapies Inc Usos novedosos
WO2019152697A1 (en) 2018-01-31 2019-08-08 Intra-Cellular Therapies, Inc. Novel uses

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1938016A1 (de) 1969-07-23 1971-01-28 Fischer Ohg Arzneimittelwerk Verfahren zur Herstellung von 8-(N-Methyl-N-aethanolamin)-coffein als Arzneimittel gegen Erkaeltungskrankheiten
FR2116302A1 (en) 1970-12-07 1972-07-13 Brun Lab Sa Le 8-aminotheophyllines - with coronary - vasodilator bronchodilator diuretic, spasmolytic, antiinflammatory and analgesic activity
ES2033922T3 (es) 1986-08-28 1993-04-01 Sandoz Ag Procedimiento para preparar nuevos derivados de xantina.
US5321029A (en) 1988-11-14 1994-06-14 Beecham-Wuelfing Gmbh & Co.K.G. Xanthines
GB8906792D0 (en) 1989-03-23 1989-05-10 Beecham Wuelfing Gmbh & Co Kg Treatment and compounds
FR2654935B1 (fr) 1989-11-28 1994-07-01 Lvmh Rech Utilisation de xanthines, eventuellement incorporees dans des liposomes, pour favoriser la pigmentation de la peau ou des cheveux.
GB9013750D0 (en) 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
ZA914727B (en) * 1990-06-21 1992-03-25 Schering Corp Polycyclic guanine derivatives
GB9020959D0 (en) 1990-09-26 1990-11-07 Beecham Group Plc Novel compounds
GB9020921D0 (en) 1990-09-26 1990-11-07 Beecham Group Plc Novel compounds
EP0563168B1 (de) 1990-12-21 2000-07-05 Beecham Group Plc Xanthinderivate
GB9210839D0 (en) 1992-05-21 1992-07-08 Smithkline Beecham Plc Novel compounds
GB9226532D0 (en) 1992-12-21 1993-02-17 Smithkline Beecham Plc Compounds
CN1118600A (zh) 1993-02-26 1996-03-13 先灵公司 2-苄基-多环鸟嘌呤衍生物以及制备它们的方法
GB9311920D0 (en) 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
GB9423911D0 (en) 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
US5731339A (en) 1995-04-28 1998-03-24 Zonagen, Inc. Methods and formulations for modulating the human sexual response
GB9514464D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
US5824683A (en) * 1995-11-28 1998-10-20 Schering Corporation 2'- 4'-halo- 1,1'-biphenyl!-4-yl!methyl!-5'-methyl-spiro cyclopentane-1,7' (8'H)- 3H! imidazo 2,1-b!purin!-4' (5'H)-ones
GB9612514D0 (en) 1996-06-14 1996-08-14 Pfizer Ltd Novel process
US6037346A (en) 1997-10-28 2000-03-14 Vivus, Inc. Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
US6403597B1 (en) 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
ID25871A (id) 1997-11-12 2000-11-09 Bayer Ag Imidazotriazinon tersubstitusi-2-fenil
DE19816857A1 (de) 1998-04-16 1999-10-21 Boehringer Ingelheim Pharma Neue unsymmetrisch substituierte Xanthin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
AU4501199A (en) 1998-06-03 1999-12-20 Almirall Prodesfarma S.A. 8-phenylxanthine derivatives and their use as phosphodiesterase inhibitors
US6087362A (en) 1999-03-16 2000-07-11 Pentech Pharmaceuticals, Inc. Apomorphine and sildenafil composition
US6023640A (en) 1999-03-29 2000-02-08 Ross; Jesse Method contributing to obviating male impotency
US20020091129A1 (en) 2000-11-20 2002-07-11 Mitradev Boolell Treatment of premature ejaculation
ATE395349T1 (de) * 2001-08-28 2008-05-15 Schering Corp Polycyclische guanin phosphodiesterase inhibitoren

Also Published As

Publication number Publication date
JP4450365B2 (ja) 2010-04-14
CN1315835C (zh) 2007-05-16
CN1547583A (zh) 2004-11-17
MXPA04001891A (es) 2004-06-15
JP2005502684A (ja) 2005-01-27
CA2457944C (en) 2009-09-29
CN1781920A (zh) 2006-06-07
AR036674A1 (es) 2004-09-29
CA2457944A1 (en) 2003-03-13
EP1421084B1 (de) 2008-05-14
DE60226615D1 (de) 2008-06-26
WO2003020724A1 (en) 2003-03-13
ES2302835T3 (es) 2008-08-01
EP1421084A1 (de) 2004-05-26
ATE395349T1 (de) 2008-05-15
JP2005325138A (ja) 2005-11-24
PE20030415A1 (es) 2003-05-22
US6969719B2 (en) 2005-11-29
US20030153587A1 (en) 2003-08-14

Similar Documents

Publication Publication Date Title
HK1064668A1 (en) Polycyclic guanine phosphodiesterase v inhibitors
HK1066546A1 (en) Trifluoromethylpurines as phosphodiesterase 4 inhibitors
PL373301A1 (en) Phosphodiesterase 4 inhibitors
AU9102201A (en) Xanthine phosphodiesterase v inhibitors
PL369728A1 (en) Pyrrolopyrimidines as phosphodiesterase vii inhibitors
AU6117801A (en) Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors
DE50304867D1 (en) Thiazolderivate als phosphodiesterase iv-inhibtoren
EP1423390A4 (de) Purin-hemmer von phosphodiesterase (pde) 7
HUP0401052A3 (en) Dna-pk inhibitors
HK1068140A1 (en) Xanthine phosphodiesterase v inhibitor polymorphs
AU2003254051A8 (en) Pyrazolopyrimidines as kinase inhibitors
PL351822A1 (en) Thienopyrimidines as phosphodiesterase inhibitors
EP1570847A4 (de) Phosphodiesterase 10a-hemmer
AU2003244080A1 (en) Phosphodiesterase inhibitor
GB0112802D0 (en) Pyrimidine derivatives
GB0112803D0 (en) Pyrimidine derivatives
AU2002326765A1 (en) Polycyclic guanine phosphodiesterase v inhibitors
AU2002350157A1 (en) Polycyclic guanine derivative phosphodiesterase v inhibitors
SI1296981T1 (en) Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors
AU2002317788A1 (en) Imidazotriazines for use as phosphodiesterase inhibitors
ZA200306119B (en) Trifluoromethylpurines as phosphodiesterase 4 inhibitors.
GB2405870B (en) DNA-PK inhibitors
AU2002348365A1 (en) Substituted tetracyclic pyrroloquinolone derivatives useful as phosphodiesterase inhibitors
GB0120333D0 (en) New purine derivatives
GB0115713D0 (en) New purine derivatives

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20120826